USD
$0.00
(0.00%
)At Close (As of Nov 17, 2025)
$1.13B
Market Cap
-
P/E Ratio
-2.72
EPS
$23.08
52 Week High
$14.00
52 Week Low
HEALTHCARE
Sector
| Field | Value (CHF) |
|---|---|
| Gross Profit | -$51M |
| Total Revenue | $686K |
| Cost Of Revenue | $52M |
| Costof Goods And Services Sold | $52M |
| Operating Income | -$73M |
| Selling General And Administrative | $22M |
| Research And Development | $52M |
| Operating Expenses | $22M |
| Investment Income Net | - |
| Net Interest Income | $1.5M |
| Interest Income | $2.2M |
| Interest Expense | $639K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $406K |
| Income Before Tax | -$86M |
| Income Tax Expense | -$160K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$86M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$73M |
| Ebitda | -$73M |
| Net Income | -$86M |
| Field | Value (CHF) |
|---|---|
| Total Assets | $120M |
| Total Current Assets | $105M |
| Cash And Cash Equivalents At Carrying Value | $28M |
| Cash And Short Term Investments | $28M |
| Inventory | - |
| Current Net Receivables | $777K |
| Total Non Current Assets | $15M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $13M |
| Intangible Assets Excluding Goodwill | $13M |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $71M |
| Other Current Assets | $5.5M |
| Other Non Current Assets | - |
| Total Liabilities | $47M |
| Total Current Liabilities | $44M |
| Current Accounts Payable | $5.9M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $315K |
| Total Non Current Liabilities | $2.7M |
| Capital Lease Obligations | $1.2M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $1.2M |
| Other Current Liabilities | $38M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $73M |
| Treasury Stock | - |
| Retained Earnings | -$286M |
| Common Stock | $446K |
| Common Stock Shares Outstanding | $40M |
| Field | Value (CHF) |
|---|---|
| Operating Cashflow | -$47M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $406K |
| Capital Expenditures | $230K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$18M |
| Cashflow From Financing | $54M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$86M |
| Field | Value (CHF) |
|---|---|
| Gross Profit | -$51M |
| Total Revenue | $686K |
| Cost Of Revenue | $52M |
| Costof Goods And Services Sold | $52M |
| Operating Income | -$73M |
| Selling General And Administrative | $22M |
| Research And Development | $52M |
| Operating Expenses | $22M |
| Investment Income Net | - |
| Net Interest Income | $1.5M |
| Interest Income | $2.2M |
| Interest Expense | $639K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $406K |
| Income Before Tax | -$86M |
| Income Tax Expense | -$160K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$86M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$73M |
| Ebitda | -$73M |
| Net Income | -$86M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Oculis Holding AG is a pioneering biopharmaceutical company located in Zug, Switzerland, dedicated to transforming the treatment landscape for ophthalmic diseases through its innovative topical therapies. Utilizing cutting-edge formulation technologies, Oculis targets significant unmet medical needs in vision care, aiming to improve patient outcomes with convenient and effective therapies. With a strong pipeline of products addressing both acute and chronic eye conditions, the company is well-positioned to make a substantial impact in the ophthalmology sector, thus attracting the attention of institutional investors seeking opportunities in novel therapeutic solutions.